FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Positron emission tomography (PET) is a type of imaging scan that doctors might use when diagnosing and treating non-Hodgkin’s lymphoma (NHL). It can be useful for identifying and staging the cancer.

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

PET scans were helpful in determining which patients with HER2-positive early breast cancer may be able to skip chemotherapy. Treating patients with HER2-positive early breast cancer based on positron ...

PET scans can light up tumors in the body and help doctors determine if they are cancerous or benign (noncancerous). The results of a PET scan help guide medical decisions. A PET scan is a type of ...

A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, "Deep learning-assisted lesion segmentation in PET/CT imaging: A feasibility study for salvage radiation ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...

PET scans improve diagnosis and assessment of treatment. * THE QUESTION Does a PET scan change breast cancer diagnoses and treatment decisions? * PAST STUDIES have shown that positron emission ...

Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...

Cancer patients across Kenya have been left stranded for over a month, as a crippling shortage of a crucial radiotracer has brought vital diagnostic scans to a halt, delaying detection, treatment, and ...